Abstract
Drug overdose death rates are the highest recorded in New York City (NYC). Substance use disorder (SUD) treatment termination can confer increased risk of drug overdose death. Our objective was to determine the probability of, and factors associated with, drug overdose death following SUD treatment termination. Using a retrospective longitudinal cohort design, we identified those who had NYC-based SUD treatment terminated (01/2016–06/2019) using Chief Medical Examiner and SUD treatment data. Using survival analyses, we examined drug overdose deaths ≤ 14 and ≤ 90 days following SUD treatment termination, respectively. Of 51,171 patients with SUD treatment termination, 140 and 342 had a drug overdose death < 14 and ≤ 90 days, respectively. The crude drug overdose death rate was 26.7 per 1000 person-years at-risk in the ≤ 90-day period and was 71.6 per 1000 person-years at-risk in the ≤ 14-day period. In adjusted Cox proportional hazard model examining death ≤ 14 days, those unemployed (compared to employed) and those terminated from residential treatment (compared to medically supervised withdrawal, opioid treatment programs, and outpatient treatment) were more likely to have had a drug overdose death (all p-values < 0.01). In adjusted Cox proportional hazard model examining death ≤ 90 days, non-Hispanic White people (compared to non-Hispanic Black people), those not stably housed (compared to stably housed), those unemployed and those terminated from residential treatment were more likely to have had a drug overdose death (all p-values < 0.01). Strategies to improve retention including the reassessment of program treatment termination criteria along with strategies to promote ongoing OUD treatment, engagement in harm reduction, and distribution of naloxone are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Data availability
Not applicable.
References
Hedegaard H, Miniño A, Spencer M, Warner M. Drug overdose deaths in the United States, 1999–2020. NCHS Data Brief, no 428. National Center for Health Statistics. 2021.
Gladden RM, O’Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine - 25 states, July-December 2017 to January-June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(34):737–44.
Friedman J, Shover CL. Charting the fourth wave: geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. Addiction. 2023;118(12):2477–85.
Burns M, Tang L, Chang C-CH, et al. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study. Addiction. 2022;117(12):3079–88.
Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018/08/07 2018;169(3):137–145.
Chhatwal J, Mueller PP, Chen Q, et al. Estimated reductions in opioid overdose deaths with sustainment of public health interventions in 4 US states. JAMA Netw Open. 2023;6(6):e2314925–e2314925.
Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357.
Parmar MKB, Strang J, Choo L, Meade AM, Bird SM. Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths. Addiction. 2017;112(3):502–15.
Walley AY, Lodi S, Li Y, et al. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis. Addiction. 2020;115(8):1496–508.
Rafful C, Orozco R, Rangel G, et al. Increased non-fatal overdose risk associated with involuntary drug treatment in a longitudinal study with people who inject drugs. Addiction. Jun2018;113(6):1056–63.
Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. Feb 5 2020;3(2):e1920622.
Fine DR, Lewis E, Weinstock K, Wright J, Gaeta JM, Baggett TP. Office-based addiction treatment retention and mortality among people experiencing homelessness. JAMA Netw Open. 2021;4(3):e210477–e210477.
Dhanda A, Salsitz EA. The duration dilemma in opioid agonist therapy. J Opioid Manag Jul-Aug. 2021;17(4):353–8.
Coughlin LN, Frost MC, Zhang L, Lin LA. Impact of COVID-19 on stimulant use disorder treatment: a national cohort study in the Veterans Health Administration. Drug Alcohol Depend. 2023;252:110965.
Perumalswami PV, Kilpatrick S, Frost MC, et al. The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration. Addiction. Jun2023;118(6):1062–71.
Gill MJ, Krentz HB. Unappreciated epidemiology: the churn effect in a regional HIV care programme. Int J STD AIDS. Aug2009;20(8):540–4.
Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Intl J Drug Policy. 2009;20(3):193–201.
Joudrey PJ, Khan MR, Wang EA, et al. A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Prac. 2019;14:1–14.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.
Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a cascade of care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1–10.
Jordan AE, Bachhuber MA, Tuazon E, et al. Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations. Drug Alcohol Depend. 2024;258:111283.
Hoffman KA, Foot C, Levander XA, et al. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: a mixed methods analysis. J Subst Abuse Treat. Oct2022;141:108801.
Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47(6):722–9.
Smith LR, Mittal ML, Wagner K, Copenhaver MM, Cunningham CO, Earnshaw VA. Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS). Addiction. Feb2020;115(2):354–67.
Volkow ND. Addiction should be treated, not penalized. Neuropsychopharmacology. Nov2021;46(12):2048–50.
Askari MS BM, Ko C, Tuazon, E, Mantha S, Harocopos A. Unintentional drug poisoning (overdose) deaths in New York City in 2021. New York City Department of Health and Mental Hygiene: Epi Data Brief. 2023;133.
Weiner Sg MM, Baker OP, Bernson DMPH, Schuur Jd MM. One year mortality of patients treated with naloxone for opioid overdose by emergency medical services. Subst Abus. 2022;43(1):99–103.
Acknowledgments
We are grateful for the collaboration between the NYS Office of Addiction Services and Supports, the NYC Office of Chief Medical Examiner, and the multi-agency NYC RxStat initiative that made this work possible.
Funding
No funding was received.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jordan, A.E., Jette, G., Graham, J.K. et al. Drug Overdose Death Following Substance Use Disorder Treatment Termination in New York City: A Retrospective Longitudinal Cohort Study. J Urban Health (2024). https://doi.org/10.1007/s11524-024-00893-5
Accepted:
Published:
DOI: https://doi.org/10.1007/s11524-024-00893-5